N-(3-Chloro-4-Fluorophenyl)-7-Fluoro-6-Nitroquinazolin-4-Amine CAS 162012-67-1 Purity >99.0% (HPLC)

Description:

Nomen chemicum: N-(3-Chloro-4-Fluorophenyl)-7-Fluoro-6-Nitroquinazolin-4-Amine

CAS: 162012-67-1

Puritas: >99.0% (HPLC)

Aspectus: lux Yellow ad Yellow pulverem

Afatinib Dimaleate (CAS: 850140-73-7)

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Descriptio:

Chemical Properties:

Nomen chemicum N-(3-Chloro-4-Fluorophenyl)
Synonyma N-(3-Chloro-4-Fluorophenyl)-7-Fluoro-6-Nitro-4-Quinazolinamine;(3-Chloro-4-Fluorophenyl)(7-Fluoro-6-Nitroquinazolin-4-yl)amine;4-(3-Chloro-4-Fluoroanilino)-7-Fluoro-6-Nitroquinazolino;Afatinib medium A
CAS Number 162012-67-1
CATTUS Number RF-PI2026
Stock Status In Stock, Productio Ascendite ad Tons
Formulae hypotheticae C14H7ClF2N4O2
M. Pondus 336.68
Sensibilitas Aer Sensitivus, calor Sensitivus
Liquescens punctum 242.0~ 244.0℃
Ferveret 489℃
Density 1.616
Brand Ruifu Chemical

Specifications:

Item Specifications
Aspectus Lux Yellow ad Yellow pulverem
Puritas / Analysis Methodus >99.0% (HPLC)
Damnum in Siccatio <0.50%
Residere in Ignition <0.20%
Substantiae cognatae
Individual Impurity <0.50%
Totalis immunditias <1.00%
Metalla gravis ≤20ppm
Infrared Imaginis Conformat ut Structure
Proton NMR Spectrum Conformat ut Structure
Test Standard Enterprise Standard
Consuetudinem Afatinib Dimaleate (CAS: 850140-73-7)

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore

commoda:

1

FAQ:

Applicatio:

N-(3-Chloro-4-Fluorophenyl)-7-Fluoro-6-Nitroquinazolin-4-Amine (CAS: 162012-67-1) medium est in synthesi Afatinib Dimaleate (CAS: 850140-73-7); .Afatinib Dimaleate eft salis forma Afatinib.Afatinib est secunda generatio, viva voce administrata, inhibitor irreversibilis familiae tyrosinae kinasium ErbB.Mechanismus actionis Afatinib downregulat ErbB significans per covalenter ligare kinasas ditiones incrementi epidermalis factoris receptoris (EGFR), factor incrementi humani epidermalis receptoris (ER) 2 et HER4, in inhibitione tyrosini kinasi autophosphorylatione irreversibili resultans;vetat etiam transphosphorylationem HER3.Afatinib sicut monotherapia approbatur ad tractationem EGFR tyrosini kinasi inhibitoris (TKI) adulti -sini cum progressu locali seu DefinitionChEBI: Sal maleatum iungendo afatinib cum duobus adaequationibus molaris acidi maleici.Usus primae lineae curationis aegrorum cum cancro metastatico cellae pulmonis non parvae.

Epistulam tuam hic scribe et mitte nobis